Suppr超能文献

[125I]-PD151242:一种人肾中内皮素ETA受体的选择性配体,定位于肾血管系统。

[125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

作者信息

Davenport A P, Kuc R E, Hoskins S L, Karet F E, Fitzgerald F

机构信息

Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital.

出版信息

Br J Pharmacol. 1994 Dec;113(4):1303-10. doi: 10.1111/j.1476-5381.1994.tb17140.x.

Abstract
  1. The linear tetrapeptide radioligand, [125I]-PD151242 was used to characterize ETA receptors in human kidney which is an ETB-rich tissue. Saturation binding assays with [125I]-PD151242 revealed a single population of high affinity endothelin receptors: KD = 0.75 +/- 0.07 nM and Bmax = 48.4 +/- 1.6 fmol mg-1 protein (n = 3 individuals +/- s.e.mean). Hill slopes were close to unity and a one site fit was preferred to a two site model. 2. ETA-receptor-selective ligands competed for [125I]-PD151242 binding with sub-nanomolar affinity: BQ123 KD = 0.43 +/- 0.10 nM, Bmax = 46.6 +/- 7.9 fmol mg-1 protein; FR139317, KD = 0.37 +/- 0.06 nM, Bmax = 39.5 +/- 6.5 fmol mg-1 protein (n = 3 individuals +/- s.e.mean). In each case, monophasic inhibition curves were obtained and a one site fit was preferred to a two site model. The ETB-selective agonist, BQ3020 at the highest concentration tested (10 microM) inhibited binding by only 50%. The non-selective RO462005 competed for the binding of [125I]-PD151242: KD = 1.31 +/- 1.38 microM, Bmax = 33.0 +/- 9.7 fmol mg-1 protein. Endothelin-2 and sarafotoxin S6B inhibited [125I]-PD151242 binding to renal tissue whereas ET-3 and sarafotoxin S6C were less effective. Non-endothelin and non-sarafotoxin peptides did not compete. 3. No degradation of [125I]-PD151242 was detected following incubation of the ligand with renal tissue under the conditions of the binding assay. 4. Polymerase chain reaction products corresponding to the expected size for mRNA encoding ETA and ETB receptor sub-types were detected in cortex and medulla in each of the five individuals examined.5. Autoradiographical studies showed that ETA receptors visualised with ['25I]-PD151242 were mainly localized to blood vessels including interlobular and arcuate arteries, arterioles and adjacent arcuate veins. ETB receptors localized with ['251]-BQ3020 were concentrated in the medulla and the density of binding to vessels was low.6. These data suggest [251I]-PDl51242 is selective for ETA receptors in human kidney and this sub-type is mainly localized to the renal vasculature. The results provide further evidence that the human vasculature mainly expresses the ETA receptor.
摘要
  1. 线性四肽放射性配体[¹²⁵I]-PD151242用于表征人肾中的ETA受体,人肾是富含ETB的组织。用[¹²⁵I]-PD151242进行的饱和结合试验显示存在单一群体的高亲和力内皮素受体:解离常数(KD)=0.75±0.07 nM,最大结合容量(Bmax)=48.4±1.6 fmol mg⁻¹蛋白质(n = 3个个体±标准误均值)。希尔斜率接近1,单位点拟合比双位点模型更合适。2. ETA受体选择性配体以亚纳摩尔亲和力竞争[¹²⁵I]-PD151242的结合:BQ123的KD = 0.43±0.10 nM,Bmax = 46.6±7.9 fmol mg⁻¹蛋白质;FR139317的KD = 0.37±0.06 nM,Bmax = 39.5±6.5 fmol mg⁻¹蛋白质(n = 3个个体±标准误均值)。在每种情况下,均获得单相抑制曲线,单位点拟合比双位点模型更合适。ETB选择性激动剂BQ3020在最高测试浓度(10 μM)时仅抑制50%的结合。非选择性的RO462005竞争[¹²⁵I]-PD151242的结合:KD = 1.31±1.38 μM,Bmax = 33.0±9.7 fmol mg⁻¹蛋白质。内皮素-2和铃蟾毒素S6B抑制[¹²⁵I]-PD151242与肾组织的结合,而ET-3和铃蟾毒素S6C的作用较弱。非内皮素和非铃蟾毒素肽不竞争。3. 在结合试验条件下,将配体与肾组织孵育后,未检测到[¹²⁵I]-PD151242的降解。4. 在检测的5个个体的皮质和髓质中均检测到与编码ETA和ETB受体亚型的mRNA预期大小相对应的聚合酶链反应产物。5. 放射自显影研究表明,用[¹²⁵I]-PD151242显示的ETA受体主要定位于血管,包括小叶间动脉、弓形动脉、小动脉和相邻的弓形静脉。用[¹²⁵I]-BQ3020定位的ETB受体集中在髓质,与血管的结合密度较低。6. 这些数据表明[¹²⁵I]-PD151242对人肾中的ETA受体具有选择性,且该亚型主要定位于肾血管系统。结果进一步证明人类血管系统主要表达ETA受体。
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4470/1510473/961a7607a3ac/brjpharm00173-0238-a.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验